IP Library › Granted Patent US 7,906,644
Granted Patent B2
US 7,906,644 · App. 11/539,013 · Granted Mar 15, 2011

2,4-pyrimidinediamine compounds and their uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,644
App. No.
11/539,013
Granted
Mar 15, 2011
Kind
B2
Abstract

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Claims (2)

1. A compound of formula:

or a salt or N-oxide thereof.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2007
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD; MOLINEAUX, SUSAN; HOLLAND, SACHA J; CLOUGH, JEFFREY; KEIM, HOLGER; BHAMIDIPATI, SOMASEKHAR; SYLVAIN, CATHERINE; LI, HUI; ROSSI, ALEXANDER B
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 019106/0736 →